AU2003243074B2 - A buffered, liquid nicotine composition for pulmonary administration - Google Patents
A buffered, liquid nicotine composition for pulmonary administration Download PDFInfo
- Publication number
- AU2003243074B2 AU2003243074B2 AU2003243074A AU2003243074A AU2003243074B2 AU 2003243074 B2 AU2003243074 B2 AU 2003243074B2 AU 2003243074 A AU2003243074 A AU 2003243074A AU 2003243074 A AU2003243074 A AU 2003243074A AU 2003243074 B2 AU2003243074 B2 AU 2003243074B2
- Authority
- AU
- Australia
- Prior art keywords
- nicotine
- pharmaceutical formulation
- liquid pharmaceutical
- formulation according
- tobacco
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title claims description 225
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title claims description 222
- 229960002715 nicotine Drugs 0.000 title claims description 220
- 239000007788 liquid Substances 0.000 title claims description 81
- 239000000203 mixture Substances 0.000 title claims description 53
- 230000002685 pulmonary effect Effects 0.000 title description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 75
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 64
- 241000208125 Nicotiana Species 0.000 claims description 63
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 50
- 238000009472 formulation Methods 0.000 claims description 34
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 30
- 210000004072 lung Anatomy 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 150000003839 salts Chemical group 0.000 claims description 14
- 239000000443 aerosol Substances 0.000 claims description 12
- 239000012458 free base Substances 0.000 claims description 12
- 239000006172 buffering agent Substances 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 230000001105 regulatory effect Effects 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 230000003139 buffering effect Effects 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- -1 mono-carbonate Chemical compound 0.000 claims description 7
- 230000029219 regulation of pH Effects 0.000 claims description 7
- 239000001117 sulphuric acid Substances 0.000 claims description 7
- 235000011149 sulphuric acid Nutrition 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 206010012335 Dependence Diseases 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 6
- 208000016620 Tourette disease Diseases 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 238000004260 weight control Methods 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 3
- 150000008043 acidic salts Chemical class 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 229910017604 nitric acid Inorganic materials 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 claims description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
- 229920000469 amphiphilic block copolymer Polymers 0.000 claims description 2
- 125000000129 anionic group Chemical group 0.000 claims description 2
- 239000003945 anionic surfactant Substances 0.000 claims description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
- 239000000920 calcium hydroxide Substances 0.000 claims description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 2
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000292 calcium oxide Substances 0.000 claims description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 239000003093 cationic surfactant Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 229940050410 gluconate Drugs 0.000 claims description 2
- 229940049920 malate Drugs 0.000 claims description 2
- 239000002736 nonionic surfactant Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229940071207 sesquicarbonate Drugs 0.000 claims description 2
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 239000002888 zwitterionic surfactant Substances 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 229910021653 sulphate ion Inorganic materials 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 description 65
- 239000000779 smoke Substances 0.000 description 27
- 230000009467 reduction Effects 0.000 description 25
- 239000004615 ingredient Substances 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 235000019504 cigarettes Nutrition 0.000 description 11
- 239000012153 distilled water Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 210000000214 mouth Anatomy 0.000 description 9
- 235000019788 craving Nutrition 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 235000015218 chewing gum Nutrition 0.000 description 7
- 239000007937 lozenge Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000007921 spray Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 238000002670 nicotine replacement therapy Methods 0.000 description 6
- 208000025569 Tobacco Use disease Diseases 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 150000007522 mineralic acids Chemical class 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 239000002585 base Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000001055 chewing effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 230000002411 adverse Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 235000019506 cigar Nutrition 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 239000007922 nasal spray Substances 0.000 description 3
- 239000006199 nebulizer Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- RFEJUZJILGIRHQ-OMDKHLBYSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;3-[(2s)-1-methylpyrrolidin-2-yl]pyridine Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.CN1CCC[C@H]1C1=CC=CN=C1 RFEJUZJILGIRHQ-OMDKHLBYSA-N 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000012387 aerosolization Methods 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 229940001468 citrate Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000018984 mastication Effects 0.000 description 2
- 238000010077 mastication Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000005586 smoking cessation Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001839 systemic circulation Effects 0.000 description 2
- 239000012808 vapor phase Substances 0.000 description 2
- ZTNBSFMIFOLVCM-UHFFFAOYSA-N 20S-Dimethylamino-3alpha-methoxypregn-5-ene Natural products C12CCC3(C)C(C(C)N(C)C)CCC3C2CC=C2C1(C)CCC(OC)C2 ZTNBSFMIFOLVCM-UHFFFAOYSA-N 0.000 description 1
- PZZXYDQKZIGACT-UHFFFAOYSA-N 5-hydroxyskytanthine Natural products C1N(C)CC(C)C2(O)C1C(C)CC2 PZZXYDQKZIGACT-UHFFFAOYSA-N 0.000 description 1
- YCPXWRQRBFJBPZ-UHFFFAOYSA-N 5-sulfosalicylic acid Chemical compound OC(=O)C1=CC(S(O)(=O)=O)=CC=C1O YCPXWRQRBFJBPZ-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- 206010052437 Nasal discomfort Diseases 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000004479 aerosol dispenser Substances 0.000 description 1
- GRTOGORTSDXSFK-XJTZBENFSA-N ajmalicine Chemical compound C1=CC=C2C(CCN3C[C@@H]4[C@H](C)OC=C([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 GRTOGORTSDXSFK-XJTZBENFSA-N 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000003113 alkalizing effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229940127225 asthma medication Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000021317 sensory perception Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0201669-9 | 2002-06-03 | ||
| SE0201669A SE0201669D0 (sv) | 2002-06-03 | 2002-06-03 | New formulation and use thereof |
| PCT/SE2003/000890 WO2003101454A1 (en) | 2002-06-03 | 2003-05-30 | A buffered, liquid nicotine composition for pulmonary administration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003243074A1 AU2003243074A1 (en) | 2003-12-19 |
| AU2003243074B2 true AU2003243074B2 (en) | 2008-11-20 |
Family
ID=20288046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003243074A Expired AU2003243074B2 (en) | 2002-06-03 | 2003-05-30 | A buffered, liquid nicotine composition for pulmonary administration |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1509227B9 (https=) |
| JP (2) | JP4745658B2 (https=) |
| CN (1) | CN100500148C (https=) |
| AR (1) | AR039947A1 (https=) |
| AT (1) | ATE444753T1 (https=) |
| AU (1) | AU2003243074B2 (https=) |
| BR (1) | BR0311451A (https=) |
| CA (1) | CA2487699C (https=) |
| DE (1) | DE60329592D1 (https=) |
| DK (1) | DK1509227T3 (https=) |
| ES (1) | ES2332405T3 (https=) |
| IL (1) | IL165195A0 (https=) |
| MX (1) | MXPA04012041A (https=) |
| NZ (1) | NZ536863A (https=) |
| RU (1) | RU2283111C2 (https=) |
| SE (1) | SE0201669D0 (https=) |
| TW (1) | TW200407142A (https=) |
| WO (1) | WO2003101454A1 (https=) |
| ZA (1) | ZA200409793B (https=) |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
| ES2285233T3 (es) | 2002-12-20 | 2007-11-16 | Niconovum Ab | Un material en particulas que contiene nicotina y celulosa microcristalina fisicamente y quimicamente estable. |
| CN100381083C (zh) | 2003-04-29 | 2008-04-16 | 韩力 | 一种非可燃性电子喷雾香烟 |
| CN2719043Y (zh) | 2004-04-14 | 2005-08-24 | 韩力 | 雾化电子烟 |
| RS56037B1 (sr) | 2004-06-24 | 2017-09-29 | Vertex Pharma | Modulatori atp-vezujućih kasetnih transportera |
| US10244793B2 (en) | 2005-07-19 | 2019-04-02 | Juul Labs, Inc. | Devices for vaporization of a substance |
| EP3219705B1 (en) | 2005-12-28 | 2020-03-11 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US9402809B2 (en) | 2006-03-16 | 2016-08-02 | Niconovum Usa, Inc. | Snuff composition |
| CN201067079Y (zh) | 2006-05-16 | 2008-06-04 | 韩力 | 仿真气溶胶吸入器 |
| NZ620027A (en) * | 2007-09-14 | 2015-05-29 | Vertex Pharma | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| AT507187B1 (de) | 2008-10-23 | 2010-03-15 | Helmut Dr Buchberger | Inhalator |
| CN201379072Y (zh) | 2009-02-11 | 2010-01-13 | 韩力 | 一种改进的雾化电子烟 |
| PL2408750T3 (pl) | 2009-03-20 | 2016-02-29 | Vertex Pharma | Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy |
| NZ599060A (en) * | 2009-09-16 | 2014-10-31 | Philip Morris Products Sa | Improved device and method for delivery of a medicament |
| AT510837B1 (de) | 2011-07-27 | 2012-07-15 | Helmut Dr Buchberger | Inhalatorkomponente |
| EP2672847B1 (de) | 2011-02-11 | 2015-04-22 | Batmark Limited | Inhalatorkomponente |
| US8903228B2 (en) | 2011-03-09 | 2014-12-02 | Chong Corporation | Vapor delivery devices and methods |
| US9399110B2 (en) | 2011-03-09 | 2016-07-26 | Chong Corporation | Medicant delivery system |
| WO2012120487A2 (en) | 2011-03-09 | 2012-09-13 | Chong Corporation | Medicant delivery system |
| KR102196913B1 (ko) | 2011-09-06 | 2020-12-30 | 니코벤처스 트레이딩 리미티드 | 가열식 흡연가능 재료 |
| KR101752639B1 (ko) | 2011-09-06 | 2017-06-30 | 브리티시 아메리칸 토바코 (인베스트먼츠) 리미티드 | 가열식 끽연 가능 물질 |
| US9907748B2 (en) * | 2011-10-21 | 2018-03-06 | Niconovum Usa, Inc. | Excipients for nicotine-containing therapeutic compositions |
| AT511344B1 (de) | 2011-10-21 | 2012-11-15 | Helmut Dr Buchberger | Inhalatorkomponente |
| JP2015511583A (ja) | 2012-02-27 | 2015-04-20 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 薬学的組成物およびその投与 |
| GB201207039D0 (en) | 2012-04-23 | 2012-06-06 | British American Tobacco Co | Heating smokeable material |
| GB2504076A (en) | 2012-07-16 | 2014-01-22 | Nicoventures Holdings Ltd | Electronic smoking device |
| GB2504075A (en) | 2012-07-16 | 2014-01-22 | Nicoventures Holdings Ltd | Electronic smoking device |
| GB201215273D0 (en) * | 2012-08-28 | 2012-10-10 | Kind Consumer Ltd | Nicotine composition |
| GB201215282D0 (en) | 2012-08-28 | 2012-10-10 | Kind Consumer Ltd | An inhaler |
| US10279934B2 (en) | 2013-03-15 | 2019-05-07 | Juul Labs, Inc. | Fillable vaporizer cartridge and method of filling |
| GB2513637A (en) | 2013-05-02 | 2014-11-05 | Nicoventures Holdings Ltd | Electronic cigarette |
| GB2513639A (en) | 2013-05-02 | 2014-11-05 | Nicoventures Holdings Ltd | Electronic cigarette |
| WO2014182736A1 (en) * | 2013-05-06 | 2014-11-13 | Ploom, Inc. | Nicotine salt formulations for aerosol devices and methods thereof |
| WO2014190079A2 (en) | 2013-05-22 | 2014-11-27 | Njoy, Inc. | Compositions, devices, and methods for nicotine aerosol delivery |
| GB2514893B (en) | 2013-06-04 | 2017-12-06 | Nicoventures Holdings Ltd | Container |
| US10251422B2 (en) | 2013-07-22 | 2019-04-09 | Altria Client Services Llc | Electronic smoking article |
| US10159282B2 (en) | 2013-12-23 | 2018-12-25 | Juul Labs, Inc. | Cartridge for use with a vaporizer device |
| US10076139B2 (en) | 2013-12-23 | 2018-09-18 | Juul Labs, Inc. | Vaporizer apparatus |
| DE202014011261U1 (de) | 2013-12-23 | 2018-11-13 | Juul Labs Uk Holdco Limited | Systeme für eine Verdampfungsvorrichtung |
| USD825102S1 (en) | 2016-07-28 | 2018-08-07 | Juul Labs, Inc. | Vaporizer device with cartridge |
| US20160366947A1 (en) | 2013-12-23 | 2016-12-22 | James Monsees | Vaporizer apparatus |
| US10058129B2 (en) | 2013-12-23 | 2018-08-28 | Juul Labs, Inc. | Vaporization device systems and methods |
| USD842536S1 (en) | 2016-07-28 | 2019-03-05 | Juul Labs, Inc. | Vaporizer cartridge |
| US9839238B2 (en) | 2014-02-28 | 2017-12-12 | Rai Strategic Holdings, Inc. | Control body for an electronic smoking article |
| GB201407426D0 (en) | 2014-04-28 | 2014-06-11 | Batmark Ltd | Aerosol forming component |
| US9896429B2 (en) | 2014-05-27 | 2018-02-20 | R.J. Reynolds Tobacco Company | Nicotine salts, co-crystals, and salt co-crystal complexes |
| US10508096B2 (en) | 2014-05-27 | 2019-12-17 | R.J. Reynolds Tobacco Company | Nicotine salts, co-crystals, and salt co-crystal complexes |
| CN113754634A (zh) | 2014-05-27 | 2021-12-07 | R.J.雷诺兹烟草公司 | 烟碱盐、共晶体和盐共晶体络合物 |
| GB2528673B (en) | 2014-07-25 | 2020-07-01 | Nicoventures Holdings Ltd | Aerosol provision system |
| CN107250113B (zh) | 2014-10-07 | 2019-03-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调节蛋白的调节剂的共晶 |
| GB2535427A (en) * | 2014-11-07 | 2016-08-24 | Nicoventures Holdings Ltd | Solution |
| GB2532062A (en) * | 2014-11-07 | 2016-05-11 | Nicoventures Holdings Ltd | Container |
| EP3821735B1 (en) | 2014-12-05 | 2024-11-20 | Juul Labs, Inc. | Calibrated dose control |
| GB2533135B (en) | 2014-12-11 | 2020-11-11 | Nicoventures Holdings Ltd | Aerosol provision systems |
| GB201505597D0 (en) | 2015-03-31 | 2015-05-13 | British American Tobacco Co | Article for use with apparatus for heating smokable material |
| GB201505595D0 (en) | 2015-03-31 | 2015-05-13 | British American Tobacco Co | Cartridge for use with apparatus for heating smokeable material |
| GB201511361D0 (en) | 2015-06-29 | 2015-08-12 | Nicoventures Holdings Ltd | Electronic vapour provision system |
| GB201511349D0 (en) | 2015-06-29 | 2015-08-12 | Nicoventures Holdings Ltd | Electronic aerosol provision systems |
| US11924930B2 (en) | 2015-08-31 | 2024-03-05 | Nicoventures Trading Limited | Article for use with apparatus for heating smokable material |
| US20170055584A1 (en) | 2015-08-31 | 2017-03-02 | British American Tobacco (Investments) Limited | Article for use with apparatus for heating smokable material |
| GB201516729D0 (en) * | 2015-09-22 | 2015-11-04 | The Technology Partnership Plc | Liquid nicotine formulation |
| GB2542838B (en) | 2015-10-01 | 2022-01-12 | Nicoventures Trading Ltd | Aerosol provision system |
| US20170119046A1 (en) | 2015-10-30 | 2017-05-04 | British American Tobacco (Investments) Limited | Apparatus for Heating Smokable Material |
| DK3379952T3 (da) * | 2015-11-25 | 2024-01-08 | Reynolds Tobacco Co R | Nikotinsalte, co-krystaller og salt-co-krystalkomplekser |
| US9867397B2 (en) | 2016-01-11 | 2018-01-16 | Patrick Beymer | Nicotine delivery system |
| EP3413960B1 (en) | 2016-02-11 | 2021-03-31 | Juul Labs, Inc. | Fillable vaporizer cartridge and method of filling |
| EA039727B1 (ru) | 2016-02-11 | 2022-03-04 | Джуул Лэбз, Инк. | Надежно прикрепляющиеся картриджи для испарительных устройств |
| JP2019512470A (ja) * | 2016-02-29 | 2019-05-16 | ニコゲン リミテッド | ニコチン配合物及びエアロゾル |
| US10405582B2 (en) | 2016-03-10 | 2019-09-10 | Pax Labs, Inc. | Vaporization device with lip sensing |
| WO2017187148A1 (en) | 2016-04-27 | 2017-11-02 | Nicoventures Holdings Limited | Electronic aerosol provision system and vaporizer therefor |
| USD849996S1 (en) | 2016-06-16 | 2019-05-28 | Pax Labs, Inc. | Vaporizer cartridge |
| USD851830S1 (en) | 2016-06-23 | 2019-06-18 | Pax Labs, Inc. | Combined vaporizer tamp and pick tool |
| USD848057S1 (en) | 2016-06-23 | 2019-05-07 | Pax Labs, Inc. | Lid for a vaporizer |
| USD836541S1 (en) | 2016-06-23 | 2018-12-25 | Pax Labs, Inc. | Charging device |
| CN111212576A (zh) * | 2017-06-26 | 2020-05-29 | 纳德尼古丁公司 | 烟碱盐及其制备和使用方法 |
| USD887632S1 (en) | 2017-09-14 | 2020-06-16 | Pax Labs, Inc. | Vaporizer cartridge |
| GB2569940B (en) * | 2017-11-01 | 2022-10-19 | Nicoventures Trading Ltd | Aerosolisable formulation |
| EP3574902A1 (en) * | 2018-06-01 | 2019-12-04 | Yatzz Limited | Nicotine formulation and mode of delivery |
| GB201817860D0 (en) | 2018-11-01 | 2018-12-19 | Nicoventures Trading Ltd | Aerosolised formulation |
| GB201817864D0 (en) | 2018-11-01 | 2018-12-19 | Nicoventures Trading Ltd | Aerosolisable formulation |
| GB201817863D0 (en) * | 2018-11-01 | 2018-12-19 | Nicoventures Trading Ltd | Aerosolisable formulation |
| GB201817867D0 (en) * | 2018-11-01 | 2018-12-19 | Nicoventures Trading Ltd | Aerosolisable formulation |
| GB201817859D0 (en) * | 2018-11-01 | 2018-12-19 | Nicoventures Trading Ltd | Aerosolisable formulation |
| DK3773494T3 (da) | 2019-06-07 | 2022-05-02 | Ncp Nextgen As | Nikotinposesammensætning og pose dermed |
| PL3905908T3 (pl) | 2019-06-20 | 2025-03-24 | Shaheen Innovations Holding Limited | Ultradźwiękowe urządzenie rozpylające do użytku osobistego |
| US11589610B2 (en) | 2019-12-15 | 2023-02-28 | Shaheen Innovations Holding Limited | Nicotine delivery device having a mist generator device and a driver device |
| PL4292632T3 (pl) | 2019-12-15 | 2025-11-24 | Shaheen Innovations Holding Limited | Ultradźwiękowy inhalator mgiełki |
| US11666713B2 (en) | 2019-12-15 | 2023-06-06 | Shaheen Innovations Holding Limited | Mist inhaler devices |
| JP7583061B2 (ja) | 2019-12-15 | 2024-11-13 | シャヒーン イノベーションズ ホールディング リミテッド | 超音波ミスト吸入器 |
| US11911559B2 (en) | 2019-12-15 | 2024-02-27 | Shaheen Innovations Holding Limited | Ultrasonic mist inhaler |
| ES3014051T3 (en) | 2019-12-15 | 2025-04-16 | Shaheen Innovations Holding Ltd | Mist inhaler devices |
| US12538944B2 (en) | 2019-12-15 | 2026-02-03 | Shaheen Innovations Holding Limited | Nicotine delivery device with identification arrangement |
| US12121056B2 (en) | 2019-12-15 | 2024-10-22 | Shaheen Innovations Holding Limited | Hookah device |
| US12233207B2 (en) | 2019-12-15 | 2025-02-25 | Shaheen Innovations Holding Limited | Mist inhaler devices |
| US11730193B2 (en) | 2019-12-15 | 2023-08-22 | Shaheen Innovations Holding Limited | Hookah device |
| US12201144B2 (en) | 2019-12-15 | 2025-01-21 | Shaheen Innovations Holding Limited | Hookah device |
| US12213516B2 (en) | 2019-12-15 | 2025-02-04 | Shaheen Innovations Holding Limited | Ultrasonic mist inhaler |
| US11944120B2 (en) | 2019-12-15 | 2024-04-02 | Shaheen Innovations Holding Limited | Ultrasonic mist inhaler with capillary retainer |
| US11730191B2 (en) | 2019-12-15 | 2023-08-22 | Shaheen Innovations Holding Limited | Hookah device |
| US20230188901A1 (en) | 2021-12-15 | 2023-06-15 | Shaheen Innovations Holding Limited | Apparatus for transmitting ultrasonic waves |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2030862A (en) * | 1978-04-10 | 1980-04-16 | Smith A | A composition for treating drug addiction such as smoking nicotine-containing products |
| DE3241437A1 (de) * | 1982-11-10 | 1984-05-10 | Ferdinand Prof. Dr.med. 6901 Wilhelmsfeld Schmidt | Mittel zum zwecke der raucherentwoehnung und/oder fuer nebenwirkungsfreien nikotingenuss bei suchtrauchern |
| US4920989A (en) * | 1985-04-25 | 1990-05-01 | Regents Of The University Of California | Method and apparatus for aiding in the reduction of incidence of tobacco smoking |
| US4953572A (en) * | 1985-04-25 | 1990-09-04 | Rose Jed E | Method and apparatus for aiding in the reduction of incidence of tobacco smoking |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8301659D0 (en) * | 1983-01-21 | 1983-02-23 | Leo Ab | Smoking substitutes |
| US5474783A (en) * | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| US5135753A (en) * | 1991-03-12 | 1992-08-04 | Pharmetrix Corporation | Method and therapeutic system for smoking cessation |
| GB9200047D0 (en) * | 1992-01-03 | 1992-02-26 | Univ Alberta | Nicotine-containing nasal spray |
| RU2108089C1 (ru) * | 1995-05-19 | 1998-04-10 | Акционерное общество "Афродита" | Шампунь для мытья волос |
| PT906089E (pt) * | 1996-05-13 | 2004-01-30 | Novartis Consumer Health Sa | Sistema de administracao bucal |
-
2002
- 2002-06-03 SE SE0201669A patent/SE0201669D0/xx unknown
-
2003
- 2003-05-27 TW TW092114309A patent/TW200407142A/zh unknown
- 2003-05-30 RU RU2004139067/15A patent/RU2283111C2/ru active
- 2003-05-30 MX MXPA04012041A patent/MXPA04012041A/es active IP Right Grant
- 2003-05-30 JP JP2004508811A patent/JP4745658B2/ja not_active Expired - Lifetime
- 2003-05-30 ES ES03756140T patent/ES2332405T3/es not_active Expired - Lifetime
- 2003-05-30 CA CA2487699A patent/CA2487699C/en not_active Expired - Lifetime
- 2003-05-30 DE DE60329592T patent/DE60329592D1/de not_active Expired - Lifetime
- 2003-05-30 CN CNB038128098A patent/CN100500148C/zh not_active Expired - Lifetime
- 2003-05-30 DK DK03756140.4T patent/DK1509227T3/da active
- 2003-05-30 WO PCT/SE2003/000890 patent/WO2003101454A1/en not_active Ceased
- 2003-05-30 AT AT03756140T patent/ATE444753T1/de not_active IP Right Cessation
- 2003-05-30 NZ NZ536863A patent/NZ536863A/en not_active IP Right Cessation
- 2003-05-30 BR BR0311451-1A patent/BR0311451A/pt not_active Application Discontinuation
- 2003-05-30 EP EP03756140A patent/EP1509227B9/en not_active Expired - Lifetime
- 2003-05-30 AU AU2003243074A patent/AU2003243074B2/en not_active Expired
- 2003-06-02 AR ARP030101967A patent/AR039947A1/es unknown
-
2004
- 2004-11-14 IL IL16519504A patent/IL165195A0/xx unknown
- 2004-12-02 ZA ZA200409793A patent/ZA200409793B/en unknown
-
2010
- 2010-09-16 JP JP2010208203A patent/JP5430525B2/ja not_active Expired - Lifetime
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2030862A (en) * | 1978-04-10 | 1980-04-16 | Smith A | A composition for treating drug addiction such as smoking nicotine-containing products |
| DE3241437A1 (de) * | 1982-11-10 | 1984-05-10 | Ferdinand Prof. Dr.med. 6901 Wilhelmsfeld Schmidt | Mittel zum zwecke der raucherentwoehnung und/oder fuer nebenwirkungsfreien nikotingenuss bei suchtrauchern |
| US4920989A (en) * | 1985-04-25 | 1990-05-01 | Regents Of The University Of California | Method and apparatus for aiding in the reduction of incidence of tobacco smoking |
| US4953572A (en) * | 1985-04-25 | 1990-09-04 | Rose Jed E | Method and apparatus for aiding in the reduction of incidence of tobacco smoking |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5430525B2 (ja) | 2014-03-05 |
| ES2332405T3 (es) | 2010-02-04 |
| JP4745658B2 (ja) | 2011-08-10 |
| DK1509227T3 (da) | 2010-02-01 |
| EP1509227B1 (en) | 2009-10-07 |
| AU2003243074A1 (en) | 2003-12-19 |
| NZ536863A (en) | 2007-05-31 |
| CN100500148C (zh) | 2009-06-17 |
| RU2283111C2 (ru) | 2006-09-10 |
| DE60329592D1 (de) | 2009-11-19 |
| WO2003101454A1 (en) | 2003-12-11 |
| ZA200409793B (en) | 2006-08-30 |
| CA2487699A1 (en) | 2003-12-11 |
| ATE444753T1 (de) | 2009-10-15 |
| CA2487699C (en) | 2012-04-17 |
| MXPA04012041A (es) | 2005-08-16 |
| AR039947A1 (es) | 2005-03-09 |
| JP2005533770A (ja) | 2005-11-10 |
| EP1509227B9 (en) | 2010-05-19 |
| BR0311451A (pt) | 2005-03-15 |
| CN1658876A (zh) | 2005-08-24 |
| RU2004139067A (ru) | 2005-08-10 |
| TW200407142A (en) | 2004-05-16 |
| SE0201669D0 (sv) | 2002-06-03 |
| JP2010280721A (ja) | 2010-12-16 |
| EP1509227A1 (en) | 2005-03-02 |
| IL165195A0 (en) | 2005-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003243074B2 (en) | A buffered, liquid nicotine composition for pulmonary administration | |
| US8642627B2 (en) | Formulation and use thereof | |
| RU2279871C2 (ru) | Жидкая фармацевтическая композиция, содержащая никотин, для введения в полость рта | |
| CA2359813C (en) | Nicotine mucosal spray | |
| RU2118897C1 (ru) | Композиция, способствующая прекращению курения, способ снижения потребности в курении табака (варианты), способ замены курения табака (варианты) | |
| EP1409049B9 (en) | Device for the administration of a substance | |
| US20070163610A1 (en) | Formulation and Use and Manufacture Thereof | |
| US20030171408A1 (en) | Therapeutic method of delivering a medicament to avoid irritating effects on membranes of user | |
| US20120022114A1 (en) | Low-dose, non-irritating nicotine nasal composition to reduce the desire to smoke |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: PFIZER CONSUMER HEALTHCARE HEALTH AB Free format text: FORMER APPLICANT(S): PFIZER HEALTH AB |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |